Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2004, Vol. 9 ›› Issue (9): 961-965.
HUANG Yu-Hong, GAO Xiu-Mei, ZHANG Bo-Li
Received:
2004-05-27
Revised:
2004-08-11
Online:
2004-09-26
Published:
2020-11-23
CLC Number:
HUANG Yu-Hong, GAO Xiu-Mei, ZHANG Bo-Li. Research progress on adiponectin[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(9): 961-965.
1 Scheen AJ.Pathophysiology of type 2 diabetes[J]. Acta Clin Belg, 2003;58(6): 335-41 2 Takahashi M, Arita Y, Yamagata K.Genomic structure and mutations in adipose-specific gene, adiponectin[J]. Int J Obse, 2000;24: 861-8 3 Saito K, Tobe T, Minoshima. Organization of the gene for gelatin-binding protein(GBP28)[J]. Gene, 1999;229(1-2): 67-73 4 Hare K, Boutin P, Mori Y.Genetic variation in the gene encoding adiponectin is associated risk of type 2 diabetes in the Japanese population[J]. Diabetes, 2002; 51(4): 1294 5 Ohashi K, Ouchi N, Kihara S, Funahashi T, Nakamura T, Sumitsuji S, et al. Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease[J]. J Am Coll Cardiol, 2004;43(7): 1195-200 6 Vasseur F, Helbecque N, Dina C. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipoctye-secreted adiponectin hormone levels and contributes to the genetic risk for type 2 diabetes in French Caucasians[J]. Hum Mol Genet, 2002;11(21): 2607-14 7 Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB, et al. Adiponectin acts in the brain to decrease body weight[J]. Nat Med, 2004; 10(5): 524-9 8 Furukawa K, Hori M, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, et al. Adiponectin down-regulates acylcoenzyme A: cholesterol acyltransferase-1 in cultured human monocyte-derived macrophages[J]. Biochem Biophys Res Commun, 2004;317 (3): 831-6 9 Maruyoshi H, Kojima S, Funahashi T, Miyamoto S, Hokamaki J, Soejima H, et al. Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina[J]. Thromb Haemost, 2004; 91(5): 1026-30 10 Komatsu M, Ohfusa H, Sato Y, Yajima H, Yamauchi K, Aizawa T, et al. Strong inverse correlation between serum adiponectin level and heart rate-corrected QT interval in an apparently healthy population: A suggestion for a direct antiatherogenic effect of adiponectin[J]. Diabetes Care, 2004; 27(5): 1237-8 11 Ouchi N, Kihara S, Atrita Y.Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin[J]. Circulation, 1999;100(25): 2473-6 12 Ouchi N, Kihara S, Funahashi T.Reciprocal association of Creactive protein with adiponectin in blood stream and adipose tissue [J]. Circulation, 2003;107(5): 671-4 13 Arita Y, Kihara S, Ouchi N.Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell[J]. Circulation, 2002; 105(24): 2893-8 14 Mallamaci F, Zoccali C, Cuzzola F.Adiponectin in essential hypertension[J]. J Nephrol, 2002;15(5): 507-11 15 Matsuzawa Y.Adipocyte function and insulin resistance[J]. Nippon Rinsho, 2000;58(2): 338-43 16 Retnakaran R, Hanley AJ, Raif N, Connelly PW, Sermer M, Zinman B.Hypoadiponectinaemia in South Asian women during pregnancy: evidence of ethnic variation in adiponectin concentration [J]. Diabet Med, 2004;21(4): 388-92 17 Hiramatsu S, Tajiri Y, Karashima T.Lower plasma adiponectin concentration predicts the efficacy of pioglitazone in diabetic patients[J]. Diabetes Obes Metab, 2004;6(3): 231-3 18 Nakamura Y, Shimada K, Fukuda D, Shimada Y, Ehara S, Hirose M, et al. Implications of plasma concentrations of adiponectin in patients with coronary artery disease[J]. Heart, 2004;90(5): 528-33 19 Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB.Plasma adiponectin levels and risk of myocardial infarction in men[J]. JAMA, 2004; 291(14): 1730-7 20 Avogaro A, Sambataro M, Marangoni A, Pianta A, Vettor R, Pagano C, et al. Moderate alcohol consumption, glucose metabolism and lipolysis: the effect on adiponectin and tumor necrosis factor alpha[J]. J Endocrinol Invest, 2003;26(12): 1213-8 21 Togo T, Kojima K, Shoji M, Kase A, Uchikado H, Katasuse O, et al. Serum adiponectin concentrations during treatment with olanzapine or risperidone:a pilot study[J]. Int Clin Psychopharmacol, 2004;19(1): 37-40 22 Imbeault P, Pomerleau M, Harper ME, Doucet E.Unchanged fasting and postprandial adiponectin levels following a 4 d caloric restriction in young healthy men [J]. Clin Endocrinol (Oxf), 2004; 60(4): 429-33 23 Milan G, Granzotto M, Scard A. Resistin and adiponectin expression in visceral fat of obese rats:effect of weight loss[J]. Obes Res, 2002;10(11): 1095-103 24 Yang WS. Lee WJ, Funahashi T.Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin [J]. J Clin EndocrinalMetab, 2002; 87(4): 1626 25 Hotta K, Funahashi T, Arita Y.Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients[J]. Arterioscler Thromb Vasc Biol, 2000; 20: 1595-9 26 Yamauchin T, Kamon J, Waki H. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity [J]. NatMed, 2001;7:941-6 27 Maeda N, Shimomura I, Kishida K.Diet-induced insulin resistance in mice lacking adiponectin ACRP30 [J]. Nat Med, 2002;8(7): 731-7 28 Yang X, Jansson PA, Nagaev I, Jack MM, Carvalho E, Sunnerhagen KS, et al. Evidence of impaired adipogenesis in insulin resistance[J]. Biochem Biophys Res Commun, 2004;317 (4): 1045-51 29 Civitarese AE, Jenkinson CP, Richardson D, BajajM, Cusi K, Kashyap S, et al. Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of Type 2 diabetes[J]. Diabetologia, 2004 30 Combs TP, Berg AH, Obici S. Endogenous glucose production in inhibited by the adipose-derived protein Acrp30[J]. J Clin Invest, 2001;108(12): 1875-81 |
[1] | MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026. |
[2] | XIE Jingjing, YIN Hongtao, LIU Jinjin, SUN Weiming, ZHEN Donghu. Baseline serum 25-hydroxyvitamin D3 levels and risk of metabolic syndrome: a prospective cohort study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 641-652. |
[3] | HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382. |
[4] | GUO Yixun, GUAN Xiaoyin, WANG Bo, WEI Yingda, ZHANG Yan, LIN Jianhua. Research progress on pathogenesis and potential therapeutic target of sarcopenia obesity [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 341-346. |
[5] | ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074. |
[6] | LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807. |
[7] | CAI Zichun, JIANG Yuanzhen, ZHANG Chunsheng, LI Jiming. Research progress and application prospects of circRNA in cardiovascular diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 397-404. |
[8] | QUAN Haiyan, JIANG Xing, HE Lu. Recent progress of mitophagy in hepatic insulin resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 198-204. |
[9] | DAI Hongyu, YANG Kun, HU Ruchun, ZHOU Hongmei, MA Peimin, HAO Qian. Duration time and effectiveness of 0.25%ropivacaine for sciatic nerve block in patients with diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1278-1284. |
[10] | WU Yi, FANG Fang, CHEN Ying, Fan Junwei. Influence of donor and recipient CYP3A5 genotype on tacrolimus trough concentrations in the early stage after liver transplantation and its clinical significance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 631-639. |
[11] | WANG Chunling, ZHOU Renjing, FENG Rui, WU Yanneng. Effect of adiponectin 45 T/G gene polymorphism on type 2 diabetes treated with liraglutide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 312-317. |
[12] | WANG Fengling, MENG Xiangyun, CHEN Zhengxu, CAO Rongjuan, HE Zhengmin, YE Xi, WANG Cong, LI Qi. Analysis on genetic polymorphism of SLCO1B1 and ApoE in patients with cardiovascular diseases of Han nationality in Anhui area and its clinical significance for individualized use of statins [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 40-48. |
[13] | XU Yongxia, XIE Mingzhu, GONG Muxue, HUANG Jiaying, ZHAO Li, ZHU Defa. Effects of 25(OH)D on islet β-cells function in the elderly with type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1021-1026. |
[14] | YANG Ming, DONG Xiaowen, HONG Huashan. Statins for primary prevention of atherosclerotic cardiovascular disease in people 75 years of age and older [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1074-1080. |
[15] | YAN Yu, LIU Kang, LIAN Wenwen, ZHANG Zhen, HE Jun. Research progress on roles of gut microbiota in cardiovascular disease and treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 829-834. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
Full text 660
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract 89
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||